Univest
Univest
  • Markets
  • Aarti Drugs Analyst Review 2027: Record Quarter, Profit Up 83% and a P/E Half the Industry’s

    • November 17, 2026
    • Posted by: Chaitanya Auti
    • Category: Market
    No Comments
    Aarti Drugs Analyst Review 2027: Record Quarter, Profit Up 83% and a P/E Half the Industry's

    Aarti Drugs posted its highest-ever quarterly revenue, EBITDA and profit in Q2 FY27, with profit up 83% on better API pricing. It still trades at about 20 times earnings. We cover the business, margins, volume gap and 2027 triggers.

    read more
  • 3 Small-Cap API and Generics Stocks With a Strong Future Roadmap: SMS Pharmaceuticals, Aarti Drugs and Senores Pharmaceuticals

    • October 7, 2026
    • Posted by: Ankit Jaiswal
    • Category: Best Stocks
    No Comments
    3 Small-Cap API and Generics Stocks With a Strong Future Roadmap: SMS Pharmaceuticals, Aarti Drugs and Senores Pharmaceuticals

    SMS Pharmaceuticals, Aarti Drugs and Senores Pharmaceuticals compared on growth, margins, debt and valuation, with the roadmap and risks investors should track.

    read more